Table 2.
Selected phage display-derived antibodies/peptide therapeutics approved by FDA, as of Dec 06 2018.
| Product, Trade Name®, Manufacturer, FDA Approval | Type | Target | Phage Display Type | Phage Display Technology | Indication | Ref |
|---|---|---|---|---|---|---|
| Antibodies | ||||||
| Adalimumab (D2E7), Humira®, Abbott Laboratories, 2002 | IgGκ | TNFα | Humanization by guided selection, scFv | CAT | Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis | [131,133,147] |
| Ranibizumab, Lucentis®, Genentech, 2006 | Fab fragment | VEGF-A | Affinity maturation of bevacizumab by phage display | Genentech | Age-related macular degeneration, macular edema after retinal vein occlusion, diabetic macular edema, diabetic retinopathy | [133,148] |
| Belimumab, Benlysta®, GSK, 2011 | IgG1λ | BLyS | Naïve, scFv | CAT | Autoantibody-positive, systemic lupus | [133,149,150] |
| Raxibacumab, Abthrax®, GSK, 2012 | IgG1λ | Protective antigen | Naïve, scFv | CAT | Anthrax | [133,151] |
| Ramucirumab (IMC-1121B), Cyramza®, ImClone/ Lilly, 2014 | IgG1 | VEGF-R2 | Naïve, Fab | Dyax | Gastric cancer, colorectal cancer, non-small cell lung cancer | [133,152] |
| Necitumumab (IMC-11F8), Portrazza®, ImClone/ Lilly, 2015 | IgG1κ | EGFR | Naïve, Fab | Dyax | Squamous non-small cell lung cancer | [133,153] |
| Avelumab, Bavencio®, EMD Serono/ Pfizer, 2017 | IgG1λ | PD-L1 | Naïve, Fab | Dyax | Metastatic Merkel cell carcinoma | [133,154] |
| Guselkumab, Tremfya®, Janssen, 2017 | IgG1λ | P19 subunit of Interleukin 23 | Synthetic, Fab | MorphoSys | Psoriasis | [133,155] |
| Lanadelumab (DX-2930), Takhzyro®, Shire, 2018 | IgG1 | Kalikrein | Naïve, Fab | Dyax | Types I and II hereditary angioedema | [133,156,157] |
| Moxetumomab Pasudotox (HA22 or CAT-8015) Lumoxiti®, AstraZeneca, 2018 | Antibody-fusion protein | CD22 | Affinity maturation of BL22 (CAT-3888) by phage display | CAT | Relapsed or refractory hairy cell leukemia | [158,159] |
| Emapalumab-lzsg (NI-0501), Gamifant®, Novimmune/ Serono, 2018 | IgG1 | Interferon-gamma | Naïve, scFv | CAT | Primary hemophagocytic lymphohistiocytosis | [133,134] |
| Peptides | ||||||
| Ecallantide, Kalbitor®, Shire, 2009 | 60 AA polypeptide | Plasma kallikrein | - | Dyax | Hereditary angioedema | [160,161] |
| Romiplostim, Nplate®, Amgen, 2008 | Peptide Fc fusion | Thrombopoietin receptor (TPOR) |
- | Affymax | Immune thrombocytopenic purpura | [162,163] |
| Affinity ligand for Xyntha, Wyeth Pharmaceuticals | Polypeptide | Factor VIII | - | Dyax | Hemophilia A | [162,164,165] |
| Albigutide, Tanzeum®, GlaxoSmithKline, 2014 | Peptide albumin fusion | GLP-1 | - | AlbudAb | Type 2 diabetes mellitus, glycemia | [166,167,168] |
AA, amino acid; BLyS, B-lymphocyte stimulator; CAT, Cambridge Antibody Technology; EGFR, epidermal growth factor receptor; FDA, Food and Drug Administration; Fab, fragment antigen-binding; GSK, GlaxoSmithKline; IgG, immunoglobulin G; k, kappa light chain; λ, lambda light chain; PD-L1, programmed death-ligand 1; scFv, single chain fragment variable; VEGFA, vascular endothelial growth factor A; VEGF-R2, vascular endothelial growth factor receptor-2; GLP-1, glucagon-likepeptide-1 receptor; AlbudAb, domain antibodies to serum albumin.